3 completed, 2 recruiting, 1 active not recruiting, 1 not yet recruiting. 7 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 3, Recruiting 2, Active not recruiting 1, Not yet recruiting 1 |
| Phase 2 | 2 | Active not recruiting 1, Recruiting 1 |
Follow Alzheimer Disease (AD): new trials by email Literature Review of Alzheimer Disease (AD) trials Research Report on Alzheimer Disease (AD)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| DUVAX: A Phase 1 Alzheimer's Vaccine Study Targeting Amyloid-Beta and Tau DUVAX 200 µg, DUVAX 400 µg, Placebo (Adjuvant only) - Alzheimer Disease, Alzheimer Disease (AD) | Phase 1 | Recruiting | Nuravax, Inc. | 24 | 2026-09-25 | 2026-09-30 |
| Study of Neural Stem Cell-Derived Exosomes in Moderate-to-Severe Early-Onset Alzheimer's Disease Neural Stem Cell-Derived Exosomes - Alzheimer Disease (AD) | Phase 1 | Not yet recruiting | Shanghai Mental Health Center | 9 | 2026-05-01 | 2026-05-15 |
| Use of a Product Containing the Cannabinoids CBD and THC as a Treatment Strategy for Alzheimer's Disease - Alzheimer's Disease and Cannabis Clinical Trial (DAZACANN) Open-Label Phase Cannabis 50 mg of CBD and 5 mg of THC - Alzheimer Disease (AD) | Phase 1 / Phase 2 | Active not recruiting | Federal University of Latin American Integration | 61 | 2025-04-07 | 2025-08-12 |
| Phase I Clinical Study of AV-1959R: Abeta-targeting Anti-Alzheimer's Vaccine AV-1959R (Abeta vaccine) - Alzheimer Disease, Alzheimer Disease (AD) | Phase 1 | Completed | Nuravax, Inc. | 16 | 2024-06-12 | 2026-09-15 |
| Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers 18F-OP-801 - Amyotrophic Lateral Sclerosis (ALS), Parkinson Disease (PD) | Phase 1 / Phase 2 | Recruiting | Ashvattha Therapeutics, Inc. | 65 | 2023-02-02 | 2025-05-02 |
| Nasal Protollin in Early Symptomatic Alzheimer's Disease Protollin - Alzheimer Disease (AD) | Phase 1 | Completed | Brigham and Women's Hospital | 16 | 2021-11-18 | 2025-09-22 |
| Evaluation Comparing Tau PET Radiotracers, [18F]GTP1 and [18F]PI-2620 or [18F]MK-6240 in Subjects With Normal Cognition or Prodromal to Moderate Alzheimer's Disease [18F]GTP1, [18F]PI-2620, [18F]MK-6240 - Alzheimer Disease (AD) | Phase 1 | Completed | Genentech, Inc. | 40 | 2020-10-26 | 2023-07-12 |
Alzheimer Disease (7) · Amyotrophic Lateral Sclerosis (1) · Multiple Sclerosis (1) · Parkinson Disease (1)
Brain Diseases (7) · Central Nervous System Diseases (7) · Dementia (7) · Mental Disorders (7) · Nervous System Diseases (7) · Neurocognitive Disorders (7) · Neurodegenerative Diseases (7) · Tauopathies (7) · Autoimmune Diseases (1) · Autoimmune Diseases of the Nervous System (1) · Basal Ganglia Diseases (1) · Demyelinating Autoimmune Diseases, CNS (1) · Demyelinating Diseases (1) · Immune System Diseases (1) · Metabolic Diseases (1)
((18)F)PI-2620 (1) · (18F)GTP1 (1) · Dronabinol (1) · Protollin (1) · nabiximols (1)
Nuravax, Inc. (2) · Ashvattha Therapeutics, Inc. (1) · Brigham and Women's Hospital (1) · Federal University of Latin American Integration (1) · Genentech, Inc. (1) · Shanghai Mental Health Center (1)
United States (4) · Australia (1) · Brazil (1) · China (1)
Roman Kniazev (2) · Anahit Ghochikyan, PhD (1) · David Cribbs, PhD (1) · Farshad Moradi, MD (1) · Hovhannes Madoyan, MD (1)
R44AG091903 (1)